Related Experiment Video

Updated: Mar 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

[New orally anticoagulants and brain stroke]

Beata Kaczorowska1, Małgorzata Pawełczyk1, Monika Przybyła2

  • 1Department of Neurology and Brain Stroke, Medical University of Lodz, Poland.

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|May 29, 2016
PubMed

Insights

New oral anticoagulants (NOA) offer a safer alternative to warfarin for preventing strokes in atrial fibrillation (AF) patients, reducing bleeding risks. Further research is needed on long-term safety and cost-effectiveness.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Context:

  • Atrial fibrillation (AF) is a primary cause of ischemic stroke, necessitating effective anticoagulant therapy.
  • Traditional anticoagulants like warfarin have limitations, prompting the search for safer alternatives.
  • Risk stratification for anticoagulation in AF patients relies on CHA2DS2-VASc and HAS-BLED scores.

Purpose:

  • To evaluate the efficacy and safety of new oral anticoagulants (NOA) in preventing stroke and systemic embolism in AF patients.
  • To compare the bleeding risk profile of NOA with vitamin K antagonists (VKA).
  • To identify current gaps in knowledge regarding NOA, including long-term safety and economic viability.

Summary:

  • NOA demonstrate comparable or superior efficacy to VKAs in preventing stroke and systemic embolism in AF patients.
  • NOA are associated with a significantly lower risk of bleeding, particularly intracranial hemorrhage, compared to VKAs.
  • Clinical studies show promising results for NOA, but long-term safety data and cost-effectiveness analyses are still evolving.

Impact:

  • NOA represent a significant advancement in stroke prevention for AF patients, offering improved safety profiles.
  • The adoption of NOA may reduce the burden of stroke and associated healthcare costs.
  • Further research into long-term outcomes and economic factors will guide optimal clinical implementation of NOA.

Keywords:
anticoagulant treatmentatrial fibrillationnew oral anticoagulantsstroke

More Related Videos

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

10.4K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.7K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Regulation of Stroke Volume01:27

Regulation of Stroke Volume

The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
5.5K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K